Clinical Trial Update: GER-009-06-AVX Early Therapy in Multiple Sclerosis

View source ↗

Summary

Biogen-sponsored trial evaluating early therapy with GER-009-06-AVX in Relapsing-Remitting Multiple Sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GER-009-06-AVX

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: COMPLETED